Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications.
van Rhijn BW, Musquera M, Liu L, Vis AN, Zuiverloon TC, van Leenders GJ, Kirkels WJ, Zwarthoff EC, Boevé ER, Jöbsis AC, Bapat B, Jewett MA, Zlotta AR, van der Kwast TH. van Rhijn BW, et al. Among authors: bapat b. Mod Pathol. 2015 May;28(5):695-705. doi: 10.1038/modpathol.2014.154. Epub 2014 Nov 28. Mod Pathol. 2015. PMID: 25431236 Free article.
The FGFR3 mutation is related to favorable pT1 bladder cancer.
van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, Zlotta AR, Bapat B. van Rhijn BW, et al. Among authors: bapat b. J Urol. 2012 Jan;187(1):310-4. doi: 10.1016/j.juro.2011.09.008. Epub 2011 Nov 17. J Urol. 2012. PMID: 22099989
Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.
van Rhijn BW, Liu L, Vis AN, Bostrom PJ, Zuiverloon TC, Fleshner NE, van der Aa MN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, Bapat B, van der Kwast TH, Zlotta AR. van Rhijn BW, et al. Among authors: bapat b. BJU Int. 2012 Oct;110(8):1169-76. doi: 10.1111/j.1464-410X.2012.10996.x. Epub 2012 Mar 27. BJU Int. 2012. PMID: 22448597
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW. Pouessel D, et al. Among authors: bapat b. Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18. Ann Oncol. 2016. PMID: 27091807 Free PMC article.
Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
Skeldon SC, Semotiuk K, Aronson M, Holter S, Gallinger S, Pollett A, Kuk C, van Rhijn B, Bostrom P, Cohen Z, Fleshner NE, Jewett MA, Hanna S, Shariat SF, Van Der Kwast TH, Evans A, Catto J, Bapat B, Zlotta AR. Skeldon SC, et al. Among authors: bapat b. Eur Urol. 2013 Feb;63(2):379-85. doi: 10.1016/j.eururo.2012.07.047. Epub 2012 Aug 2. Eur Urol. 2013. PMID: 22883484
A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade.
Hermanns T, Savio AJ, Olkhov-Mitsel E, Mari A, Wettstein MS, Saba K, Bhindi B, Kuk C, Poyet C, Wild PJ, Noon A, Bashir S, Juvet T, Rendon RA, Waltregny D, van der Kwast T, Finelli A, Kulkarni GS, Fleshner NE, Lo K, Bapat B, Zlotta AR. Hermanns T, et al. Among authors: bapat b. Urol Oncol. 2020 Jun;38(6):603.e1-603.e7. doi: 10.1016/j.urolonc.2020.01.007. Epub 2020 Feb 18. Urol Oncol. 2020. PMID: 32081560
204 results